This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies
by Zacks Equity Research
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
GSKNegative Net Change CRMDNegative Net Change IONSNegative Net Change KROSNegative Net Change
biotechs medical pharmaceuticals
CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois
by Zacks Equity Research
Centene expands its Medicaid strategy by partnering with Cityblock Health to serve 10,000 Illinois members with 24/7 wrap-around care.
RIGLNegative Net Change CNCPositive Net Change CRMDNegative Net Change EXASPositive Net Change
insurance medical
Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell?
by Debanjana Dey
HIMS expands into Canada and the U.K. while revenue and subscribers grow. However, margins and execution raise concerns.
TDOCPositive Net Change HIMSNegative Net Change DOCSNegative Net Change
medical medical-devices
INGN Stock Gains Post Latest Launch to Expand Respiratory Care Suite
by Zacks Equity Research
Inogen launches Aurora CPAP masks to expand its respiratory care suite and enter the growing sleep apnea market.
BSXNegative Net Change CAHNegative Net Change IDXXNegative Net Change INGNNegative Net Change
medical medical-devices
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
Shares of Krystal Biotech soar 57% in a year as strong Vyjuvek uptake and steady pipeline progress continue to push the stock higher.
FOLDNegative Net Change CRMDNegative Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
The Zacks Analyst Blog Highlights Micron Technology, Roche and UnitedHealth
by Zacks Equity Research
Micron Technology, Roche and UnitedHealth highlight diverging opportunities across technology, pharmaceuticals and managed care.
RHHBYNegative Net Change UNHPositive Net Change MUNegative Net Change
computers medical pharmaceuticals
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics
by Zacks Equity Research
Soleno Therapeutics leads a rebound in small drug stocks as innovation, pipeline progress and M&A activity fuel optimism for 2026.
IRWDNegative Net Change NKTRNegative Net Change RIGLNegative Net Change SLNOPositive Net Change MRKRNegative Net Change
medical pharmaceuticals
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?
by Ahan Chakraborty
Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.
PFENegative Net Change NVOPositive Net Change LLYNegative Net Change VTYXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Hospital Industry Reshaping Under Strain: 3 Stocks Worth Watching
by Kaibalya Pravo Dey
THC, UHS and CYH are showing strength through outpatient focus and efficiency-improving efforts, despite hospital industry headwinds.
THCPositive Net Change UHSPositive Net Change CYHPositive Net Change
hospitals medical
Zacks.com featured highlights include Animal Health, Commercial Metals, Fox and Adtalem Global Education
by Zacks Equity Research
Animal Health, Commercial Metals, Fox and Adtalem stand out as PEG-based GARP picks offering balanced growth and value amid early-2026 uncertainty.
CMCNegative Net Change FOXPositive Net Change PAHCPositive Net Change ATGEPositive Net Change
consumer-discretionary industrial-products medical
RVMD Stock Hits a Record High on Rumored Takeover Interest
by Zacks Equity Research
Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.
LLYNegative Net Change AMGNNegative Net Change ABBVNegative Net Change RVMDPositive Net Change
biotechs medical pharmaceuticals
4 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run. Stocks like INDV, AUGO, ERO and OI are seeing price strength, and the momentum is likely to continue.
OIPositive Net Change EROPositive Net Change INDVNegative Net Change AUGOPositive Net Change
basic-materials industrial-products medical
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.
RHHBYNegative Net Change EXELNegative Net Change FOLDNegative Net Change CRMDNegative Net Change NTRANegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for Accendra Health Stock Options
by Zacks Equity Research
Investors need to pay close attention to ACH stock based on the movements in the options market lately.
ACHPositive Net Change
medical medical-devices
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
by Zacks Equity Research
AVTR looks worth holding as its broad portfolio, strategic deals and cost savings offset Lab Solutions' weakness for now with AI tools and strong cash flow.
BSXNegative Net Change ISRGNegative Net Change MEDPNegative Net Change AVTRNegative Net Change
medical medical-devices
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
by Zacks Equity Research
BSX is seeing solid international growth, MedSurg market-share gains and surging WATCHMAN sales, though macro and competition remain risks.
BSXNegative Net Change DGXNegative Net Change PAHCPositive Net Change BTSGNegative Net Change
medical medical-devices
Is This the Right Time to Add Resmed Stock to Your Portfolio?
by Zacks Equity Research
RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could weigh on future performance.
DGXNegative Net Change RMDPositive Net Change PAHCPositive Net Change BTSGNegative Net Change
medical
Here's Why You Should Retain Cencora Stock in Your Portfolio Now
by Zacks Equity Research
Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.
BSXNegative Net Change ISRGNegative Net Change CORNegative Net Change MEDPNegative Net Change
medical medical-devices
Top Stock Reports for Micron Technology, Roche & UnitedHealth
by Mark Vickery
MU leads today's Zacks Research Daily, with AI-driven memory demand, strong DRAM pricing recovery and solid cash flow powering recent outperformance.
RHHBYNegative Net Change UNHPositive Net Change PAYXPositive Net Change WDCNegative Net Change MUNegative Net Change DXCMNegative Net Change
computers medical pharmaceuticals
Implied Volatility Surging for Guardian Pharmacy Services Stock Options
by Zacks Equity Research
Investors need to pay close attention to Guardian Pharmacy Services stock based on the movements in the options market lately.
GRDNNegative Net Change
medical medical-devices
4 PEG-Based GARP Picks for Navigating Early-2026 Market Uncertainty
by Urmimala Biswas
PAHC and others highlight how PEG-based GARP picks blend value and growth as markets hit 2026 highs amid rate uncertainty and valuation sensitivity.
CMCNegative Net Change FOXPositive Net Change PAHCPositive Net Change ATGEPositive Net Change
basic-materials consumer-discretionary medical medical-devices
Do Options Traders Know Something About FMS Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Fresenius Medical Care stock based on the movements in the options market lately.
FMSNegative Net Change
medical
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
by Zacks Equity Research
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
SNYNegative Net Change BIIBNegative Net Change DNLIPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Select Medical Expands Rehab Footprint Through Vibra Healthcare JV
by Zacks Equity Research
SEM teams up with Vibra Healthcare to run a 76-bed rehab hospital in Southern Kentucky, expanding its post-acute care footprint through a capital-efficient JV.
RIGLNegative Net Change SEMPositive Net Change CRMDNegative Net Change EXASPositive Net Change
medical smart-health
BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers
by Zacks Equity Research
Butterfly Network targets a 2026 Beam Steering API, opening core imaging to developers and enabling AI tools in Butterfly Garden.
VCYTNegative Net Change KRMDPositive Net Change SDGRNegative Net Change BFLYNegative Net Change
medical medical-devices